Sanchez, Cesar

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Rha, S. Y., Oh, D.-Y., Yañez, P., Bai, Y., Ryu, M.-H., Lee, J., Rivera, F., Alves, G. V., Garrido, M., Shiu, K.-K., et al. (2023) · The Lancet Oncology

Gastric Cancer Management and OutcomesCancer Immunotherapy and Biomarkers

Cited by 690

Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer

Rojas, L., Muñiz, S., Medina, L., Peña, J., Acevedo, F., Pinto, M. P., & Sanchez, C. (2020) · PLOS ONE

Health Systems, Economic Evaluations, Quality of LifeEconomic and Financial Impacts of Cancer

Cited by 23